Coming Soon: Advances in Multiple Myeloma: Insights from Experts at the Moffit Cancer Center

Video

Melissa Alsina, MD, shares her excitement for an upcoming program wherein she and other key opinion leaders from the Moffit Cancer Center review updated data and optimal treatment strategies in the setting of multiple myeloma.

Recent Videos
4 experts in this video
4 experts in this video
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
4 experts in this video
4 experts in this video
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Related Content
Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

ONCOLOGY Staff
August 17th 2025
Article

Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Defining the Role of Immune Therapy in Multiple Myeloma

Roman Fabbricatore
August 9th 2025
Article

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as in solid tumors and beyond, includes immune therapies.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 1st 2025
Article

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Designation to GPRC5D Target in Multiple Myeloma

Tim Cortese
July 30th 2025
Article

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.